STOCK TITAN

Dare Bioscience Inc - DARE STOCK NEWS

Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.

Overview of Dare Bioscience Inc

Dare Bioscience Inc (DARE) is a clinical-stage biopharmaceutical company committed to advancing innovative therapies for women’s health. The company is driven by a focused mission to identify, develop, and ultimately bring to market a diverse portfolio of products designed to expand treatment options and improve outcomes in key areas of women’s reproductive and sexual health. With a strong commitment to innovation, Dare Bioscience is uniquely positioned at the intersection of rigorous scientific research and patient-centric solutions that address unmet needs in contraception, vaginal health, fertility, and sexual dysfunction disorders.

Core Business and Product Portfolio

Dare Bioscience operates primarily within a single operating segment dedicated to women’s health. The company develops therapies that target multiple facets of reproductive and sexual wellness. Its portfolio includes several promising product candidates:

  • XACIATO™: The first FDA-approved product from its portfolio, this clindamycin phosphate vaginal gel is indicated for the treatment of bacterial vaginosis in women aged 12 and older and operates under a global licensing agreement.
  • Ovaprene®: A novel, hormone-free monthly intravaginal contraceptive candidate developed under partnership agreements, offering an innovative approach in non-hormonal contraception.
  • Sildenafil Cream, 3.6%: An investigational topical cream formulation designed to treat female sexual arousal disorder (FSAD) by locally enhancing genital blood flow while mitigating systemic side effects. Its development is supported by robust clinical data and exploratory analyses demonstrating improved arousal sensations and reduced sexual distress.
  • DARE-HRT1: A combination bio-identical estradiol and progesterone intravaginal ring intended for menopausal hormone therapy, further highlighting the company’s commitment to addressing diverse aspects of women’s health.
  • DARE-HPV: An innovative investigational treatment for HPV-related cervical disease. This candidate aims to be the first FDA-approved pharmaceutical intervention that addresses both late-stage cervical lesions and early-stage HPV infections, potentially transforming clinical management of cervical precancer conditions.
  • Casea S and DARE-LARC1: Reflecting the company’s efforts in contraceptive innovation, these candidates focus on long-acting, reversible contraceptives with design features such as biodegradability, precision dosing, extended duration, and wireless control, thus providing women with more convenient and minimally invasive options to manage their reproductive health.

Clinical Development, Innovation, and Strategic Partnerships

The clinical development programs at Dare Bioscience are underscored by a thorough evaluation of safety and efficacy through various phases of clinical trials. Its development strategy involves robust collaboration with regulatory authorities, extensive clinical research, and strategic partnerships. The company has secured funding and grant awards from prominent organizations, including substantial non-dilutive strategic financing, grants from private foundations, and awards from federal agencies. These funding sources are instrumental in de-risking clinical programs and supporting the advancement of product candidates such as Ovaprene, Sildenafil Cream, and DARE-HPV.

Collaborative partnerships with industry leaders and specialty pharmaceutical companies further enhance the company’s capabilities. For instance, licensing agreements and co-development partnerships enable Dare Bioscience to leverage external expertise, share the costs of clinical development, and expedite the advancement of first-in-category therapeutic solutions. The company’s approach involves meticulous trial design, including the use of patient-reported outcome measures (PROs) in conditions like FSAD, ensuring that the clinical benefits are clearly demonstrated and validated.

Market Position and Significance in Women’s Health

Within the highly competitive biopharmaceutical landscape, Dare Bioscience distinguishes itself through a dedicated focus on women’s health. The company’s innovative product candidates are designed to address conditions where there is a significant unmet medical need. By targeting areas such as non-hormonal contraception, vaginal health, fertility enhancement, and sexual dysfunction, Dare Bioscience holds a differentiated position relative to traditional pharmaceutical companies. Its scientific rigor, evidenced by the publication of clinical trial data in renowned peer-reviewed journals, establishes the company as a trusted source of advanced therapeutic solutions.

This focused approach not only broadens treatment options for patients but also aligns with the evolving demand for personalized medicine and targeted therapies within the female demographic. The company’s commitment to addressing commonly overlooked issues in women’s health helps to create a niche market with sustainable long-term growth potential.

Research, Technology, and Development Excellence

The technical foundation of Dare Bioscience’s novel therapies is built on cutting-edge research in pharmacology and drug delivery systems. The use of innovative technology, such as proprietary cream formulations and advanced intravaginal delivery systems, positions the company to overcome common limitations associated with systemic drug therapies. For example, the topical application of Sildenafil Cream minimizes systemic side effects often seen with oral formulations, while targeted delivery ensures higher local concentrations and optimal therapeutic efficacy.

Moreover, the drug delivery platforms being explored by the company have potential applications beyond women’s health, potentially addressing therapeutic needs in areas such as metabolic disorders and chronic conditions that require precise dosing. This versatility underscores the company’s research and development expertise, providing a robust platform for future product innovations.

Commitment to Scientific Rigor and Regulatory Compliance

Dare Bioscience’s path to regulatory approval is characterized by its disciplined approach to clinical trial design, patient safety, and statistical analysis. The company engages in continuous dialogue with the U.S. Food and Drug Administration (FDA) and other regulatory bodies throughout its clinical development process. This collaborative relationship ensures that the company’s clinical programs adhere to high standards of safety and efficacy, as evidenced by multiple milestone achievements and positive discussions regarding trial endpoints.

The company’s publications in key medical journals serve as external validations of its research methodology and clinical findings. By providing transparent and detailed data on patient outcomes, Dare Bioscience reinforces its commitment to rigorous scientific inquiry and maintains high levels of trust with the medical community, investors, and patients alike.

Operational Excellence and Future Research Directions

Operationally, Dare Bioscience excels in integrating research, clinical operations, and strategic capital management. The company utilizes non-dilutive financing mechanisms and maintains strategic funding partnerships to support its expansive clinical pipeline without compromising operational independence. This prudent fiscal strategy allows it to focus on breakthrough research and efficient clinical trial execution.

While the company remains committed to addressing current unmet needs in women’s health, its research infrastructure and technological platforms also lay the groundwork for exploring additional therapeutic areas in the future. The possibility of leveraging its advanced drug delivery systems in conditions beyond reproductive health highlights the innovative potential and scalable business model inherent in its approach.

Conclusion

In summary, Dare Bioscience Inc represents a sophisticated blend of targeted research, innovative product development, and strategic operational management focused on improving women’s health outcomes. Through its diversified portfolio ranging from non-hormonal contraceptives to novel therapies for conditions such as FSAD and HPV-related cervical diseases, the company addresses significant gaps in current clinical practice. Its methodical approach to regulatory interactions, rigorous clinical testing, and strategic partnerships collectively position it as a pivotal player in the evolving biopharmaceutical landscape for women’s health.

This comprehensive focus, backed by industry-recognized research, enhances the company's authority and credibility, providing a valuable resource for investors and healthcare professionals seeking to understand the impact of innovative solutions in women’s reproductive and sexual health care.

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will participate in a live panel discussion titled The Evolution of Birth Control on February 23, 2021, at 12:30 p.m. EST during the Women’s Health Innovation Series: Contraception Innovation Summit. The discussion will explore innovation challenges in birth control. Ms. Johnson will highlight Daré's commitment to women's health and the development of three innovative contraceptive candidates: Ovaprene®, DARE-LARC1, and ORB formulations. This virtual summit aims to enhance women's contraceptive experiences, featuring stakeholders from various sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
-
Rhea-AI Summary

Daré Bioscience, a leader in women’s health, announced that CEO Sabrina Martucci Johnson will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will cover innovative developments in women's health, including Daré's unique product portfolio.

Following the event, a recording will be available on Daré's investor relations website until March 4, 2021. The company focuses on developing differentiated therapies in contraception, vaginal health, sexual health, and fertility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Daré Bioscience, a leader in women’s health innovation, announced that its CEO, Sabrina Martucci Johnson, will join a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference from January 11-14, 2021. The chat will be available on-demand starting January 11, 2021, at 6:00 AM ET on the company's website and will remain accessible until January 25, 2021. Daré focuses on advancing innovative therapies for women's health, offering products like Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.11%
Tags
conferences
Rhea-AI Summary

Daré Bioscience has announced that its investigational treatment, DARE-BV1, has successfully met its primary and secondary endpoints in a Phase 3 trial for bacterial vaginosis, achieving significant clinical cure rates over placebo. The study involved 307 women, demonstrating a 70.2% cure rate at 21-30 days. The treatment has received Fast Track and QIDP designations from the FDA, with a New Drug Application (NDA) submission planned for the first half of 2021. These results indicate a promising new front-line option for women suffering from bacterial vaginosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.33%
Tags
-
Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) reported its third-quarter financial results for 2020, highlighting significant advances in its product pipeline amid a challenging environment. The company is on track to complete the DARE-BVFREE pivotal study for bacterial vaginosis and anticipates FDA submission in the first half of 2021 if results are favorable. Total expenses increased, with R&D costs rising to approximately $6.2 million due to ongoing projects like DARE-BV1 and Ovaprene. Cash and equivalents stand at $5.4 million, with recent capital raised of about $4.5 million post-quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
-
Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) will host a conference call on November 12, 2020, at 4:30 p.m. ET to discuss its financial results for Q3 2020. The event will provide insights into the company's portfolio focused on women's health, including innovative products like Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1. Investors can join via phone or webcast, with a replay available until November 19, 2020. The company's mission is to enhance treatment options in areas including contraception and male sexual health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences earnings
Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the 2020 BIO Investor Forum, held digitally from October 13-15, 2020. Registered attendees can access the presentation on demand during the event. Following the forum, a recording will be available in the Investor Relations section of the company's website until October 29, 2020. Daré is focused on innovative women's health products, including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, enhancing treatment options across various areas including contraception and sexual health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
conferences
-
Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced the receipt of approximately $0.9 million in funding from the Bill & Melinda Gates Foundation, completing a total of $19.5 million in grant support for its user-controlled long-acting reversible contraceptive (UC-LARC), DARE-LARC1. This funding will aid in advancing the preclinical development of DARE-LARC1, designed to deliver therapeutic doses without requiring medical procedures. The technology, developed by MIT researchers, aims to address the limitations of current LARCs, offering a more flexible contraceptive solution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary

Daré Bioscience, focused on women’s health, announced CEO Sabrina Martucci Johnson's participation in two virtual conferences on September 14 and 15, 2020. She will join the Women’s Health Innovation Summit's expert panel for women-centric clinical research and a CEO leadership panel, with both discussions available on-demand. Additionally, Johnson will present a company update at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 4:00 PM EDT. Live webcasts and an archive will be accessible through the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) has formed a strategic partnership with Avomeen to enhance the development of its women’s health product pipeline. This agreement will allow Avomeen to provide tailored product development laboratory services for the next three years, prioritizing projects like Ovaprene®, a hormone-free contraceptive. The collaboration aims to leverage Avomeen’s scientific expertise to improve efficiency and reduce research costs. Both companies believe this partnership will facilitate faster market introductions for innovative products targeting unmet needs in women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
partnership

FAQ

What is the current stock price of Dare Bioscience (DARE)?

The current stock price of Dare Bioscience (DARE) is $2.895 as of April 4, 2025.

What is the market cap of Dare Bioscience (DARE)?

The market cap of Dare Bioscience (DARE) is approximately 25.1M.

What is the core focus of Dare Bioscience Inc?

Dare Bioscience Inc is dedicated to developing innovative therapies for women’s health, focusing on areas such as contraception, sexual health, and reproductive wellness.

How does the company generate revenue?

The company generates revenue primarily through licensing agreements, collaborations with strategic partners, and the commercialization of its FDA-approved product candidates in women’s health.

What are the key product candidates in Dare Bioscience’s portfolio?

Their portfolio includes XACIATO™ (an antibacterial vaginal gel), Ovaprene® (a non-hormonal contraceptive candidate), Sildenafil Cream for FSAD, DARE-HRT1, and investigational treatments like DARE-HPV and Casea S.

How does Dare Bioscience ensure safety and efficacy in its clinical trials?

The company uses robust clinical trial designs, incorporates patient-reported outcome measures, and maintains continuous collaboration with regulatory authorities to ensure high standards of safety and efficacy.

What makes Dare Bioscience unique in the biopharmaceutical industry?

Its exclusive focus on women’s health, innovative drug delivery systems, and strategic partnerships, combined with a commitment to rigorous scientific research, sets it apart in the competitive biopharmaceutical landscape.

What role do strategic collaborations play in the company’s development efforts?

Strategic collaborations enable Dare Bioscience to share development costs, access additional expertise, and expedite clinical programs, thus enhancing its ability to deliver first-in-category therapies.

How does the company address unmet needs in women’s health?

Dare Bioscience targets areas with significant unmet medical needs, such as non-hormonal contraception, sexual arousal disorders, and HPV-related cervical disease, developing therapies that provide more convenient and effective treatment options.

What is the company’s approach to regulatory interactions?

The company maintains continuous dialogue with regulatory agencies like the FDA, ensuring its clinical trial designs and endpoints meet stringent safety and efficacy standards for potential product approvals.
Dare Bioscience Inc

Nasdaq:DARE

DARE Rankings

DARE Stock Data

25.13M
8.71M
1.59%
8.99%
0.82%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO